Clinical Trials Directory

A Clinical Study to Evaluate Safety of the ExAblate Model 2100 Type 1.1 System (ExAblate 2100/2000 UF V2 System) in the Treatment of Symptomatic Uterine Fibroids

The purpose of this study is to evaluate the safety and ablation efficacy of the ExAblate UF V2 System when treating symptomatic uterine fibroids. The ExAblate System is a medical device that involves a focused ultrasound system and an MRI scanner. ExAblate delivers a pulse of focused ultrasound energy, or sonication, to the targeted tissue. In this particular study, the targeted tissue is uterine fibroids. Each sonication is used to heat small spots in the fibroid much like a magnifying glass can be used to focus light to heat a spot. The heat created kills a portion of the fibroid with the goal of decreasing or eliminating uterine fibroid-related symptoms. Repeated sonications are performed until the entire fibroid is treated or the treated volume is determined to be appropriate. The ExAblate system is commercially approved in the United States to treat symptomatic uterine fibroids. The ExAblate UF V2 System is an experimental device and is being investigated in this study. While similar to the commercial system, the ExAblate UF V2 device includes the following major changes, among others, which are intended to improve device performance and safety: - Up and down movement of the ultrasound transducer, in an attempt to improve fibroid treatment by moving the ultrasound focal point within the targeted fibroid. - Ultrasound energy can be turned off for a specific area in an attempt to minimize amount of energy passing through sensitive areas of the body.

Stanford is now accepting new patients for this trial. Please contact Pejman Ghanouni, MD at 650-498-4485 for more information.

Investigator(s):

Intervention(s):

  • device : ExAblate Treatment UF V2

Phase: N/A

Eligibility

Ages Eligible For Study:

18 Years - 64 Years

Inclusion Criteria

1. Patient age 18 or older 2. Patients who present with symptomatic uterine fibroids and are not seeking treatment for the reason of improving fertility. 3. Patients who have given written informed consent 4. Patients who are able and willing to attend all study visits 5. Patients who are pre or peri-menopausal (within 12 months of last menstrual period) 6. Patients should have completed child bearing 7. Able to communicate sensations during the ExAblate procedure. 8. Uterine fibroids, which are device accessible (i.e., positioned in the uterus such that they can be accessed without being shielded by bowel or bone). 9. Fibroid(s) clearly visible on non-contrast MRI.

External Links

Contact information

Primary Contact:

Pejman Ghanouni, MD 650-498-4485

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: